“Short Bowel Syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Short Bowel Syndrome Market.
The Short Bowel Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Short Bowel Syndrome Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Short Bowel Syndrome treatment therapies with a considerable amount of success over the years.
-
Short Bowel Syndrome companies working in the treatment market are Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others, are developing therapies for the Short Bowel Syndrome treatment
-
Emerging Short Bowel Syndrome therapies in the different phases of clinical trials are- Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others are expected to have a significant impact on the Short Bowel Syndrome market in the coming years.
-
In October 2024, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a company focused on gastrointestinal healthcare, will present new results at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course. The findings come from subgroup analyses of the primary endpoint in the pivotal Phase III STARS trial, assessing apraglutide’s treatment effect in adults with short bowel syndrome with intestinal failure (SBS-IF). The data, which will be shared in an oral presentation on October 29 from 8:30 am – 8:40 am ET, show that apraglutide demonstrated a consistent treatment effect across various subgroups, including gender, age, body weight, region, race, ethnicity, and SBS characteristics, such as the length of remnant bowel. These results further support the previously reported positive data from the Phase III trial.
-
In May 2024, Jaguar Health, Inc. (NASDAQ: JAGX) announced that its subsidiary companies, Napo Pharmaceuticals and Napo Therapeutics, have submitted a Clinical Trial Application (CTA) to the health authorities in Italy and Germany to initiate a Phase 2 clinical trial for Jaguar's novel plant-based prescription drug, crofelemer, for treating short bowel syndrome (SBS) with intestinal failure in adults. Additionally, Napo Therapeutics has submitted a CTA to AIFA, the Italian health authority, to conduct a clinical trial for pediatric patients with microvillus inclusion disease (MVID). The approval process for this trial is also underway in the United Arab Emirates with Dubai Health. The MVID clinical trial is being conducted under an active US Investigational New Drug (IND) application.
-
In February 2024, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a company specializing in gastrointestinal healthcare, has unveiled promising top-line outcomes from its pivotal Phase III STARS trial. This trial assessed the effectiveness and safety of subcutaneous apraglutide administered once weekly in reducing the dependency on parenteral support (PS) in adult patients diagnosed with short bowel syndrome with intestinal failure (SBS-IF). SBS-IF is a rare and severe condition resulting in organ failure, where patients rely on PS. Approximately 18,000 adult patients in the United States, Europe, and Japan are affected by this condition. Following these findings, Ironwood intends to submit a new drug application (NDA) and other regulatory documents for apraglutide aimed at treating adult SBS patients reliant on PS.
Short Bowel Syndrome Overview
Short Bowel Syndrome (SBS) is a condition that occurs when a person has lost a significant portion of their small intestine, either due to surgery or disease. This results in the inability of the body to absorb enough nutrients and fluids from food. The severity of SBS depends on how much of the small intestine is removed and its ability to adapt. Symptoms include diarrhea, dehydration, malnutrition, and weight loss. SBS is typically managed through dietary changes, nutritional supplements, and in some cases, intravenous feeding or medications to improve nutrient absorption.
Get a Free Sample PDF Report to know more about Short Bowel Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/short-bowel-syndrome-pipeline-insight
Emerging Short Bowel Syndrome Drugs Under Different Phases of Clinical Development Include:
-
Glepaglutide: Zealand Pharma
-
Apraglutide: Ironwood Pharmaceuticals
-
HM15912: Hanmi Pharmaceutical
-
Teduglutide: Shire
-
Pancreatic Enzyme: AbbVie
-
HM15912 Active: Hanmi Pharma
-
Somatropin: EMD Serono
-
ZP1848: Zealand Pharma
-
FE203799: VectivBio AG
-
Clinolipid: Baxter Healthcare
Short Bowel Syndrome Route of Administration
Short Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravenous
-
Subcutaneous
-
Topical
Short Bowel Syndrome Molecule Type
Short Bowel Syndrome Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Short Bowel Syndrome Pipeline Therapeutics Assessment
-
Short Bowel Syndrome Assessment by Product Type
-
Short Bowel Syndrome By Stage and Product Type
-
Short Bowel Syndrome Assessment by Route of Administration
-
Short Bowel Syndrome By Stage and Route of Administration
-
Short Bowel Syndrome Assessment by Molecule Type
-
Short Bowel Syndrome by Stage and Molecule Type
DelveInsight's Short Bowel Syndrome Report covers around 20+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Short Bowel Syndrome product details are provided in the report. Download the Short Bowel Syndrome pipeline report to learn more about the emerging Short Bowel Syndrome therapies
Some of the key companies in the Short Bowel Syndrome Therapeutics Market include:
Key companies developing therapies for Short Bowel Syndrome are - VectivBio AG, 9 Meters Biopharma, Inc., Nutrinia Ltd., Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, Hanmi Pharm.Co., Ltd., and Pharmascience, Inc., and others.
Short Bowel Syndrome Pipeline Analysis:
The Short Bowel Syndrome pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Short Bowel Syndrome with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Short Bowel Syndrome Treatment.
-
Short Bowel Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Short Bowel Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Short Bowel Syndrome market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Short Bowel Syndrome drugs and therapies
Short Bowel Syndrome Pipeline Market Strengths
-
In the treatment of short bowel syndrome, GLP-2 and the long-acting GLP-2 analog are effective in improving fluid absorption. Recent clinical trials demonstrate that this can translate into meaningful reductions in parenteral nutrition requirements.
-
Current treatments are effective in relieving the symptoms and improving the quality of life of the patients
Short Bowel Syndrome Pipeline Market Opportunities
-
Several organizations are actively working to provide information and increase awareness of such disorders.
-
There are less treatment options for Short bowel syndrome which opens a platform of new therapies to boost the market of Short bowel syndrome
Scope of Short Bowel Syndrome Pipeline Drug Insight
-
Coverage: Global
-
Key Short Bowel Syndrome Companies: Zealand Pharma, Ironwood Pharmaceuticals, Hanmi Pharmaceutical, Shire, AbbVie, Hanmi Pharma, EMD Serono, Zealand Pharma, VectivBio AG, Baxter Healthcare, and others
-
Key Short Bowel Syndrome Therapies: Glepaglutide, Apraglutide, HM15912, Teduglutide, Pancreatic Enzyme, HM15912 Active, Somatropin, ZP1848, FE203799, Clinolipid, and others
-
Short Bowel Syndrome Therapeutic Assessment: Short Bowel Syndrome current marketed and Short Bowel Syndrome emerging therapies
-
Short Bowel Syndrome Market Dynamics: Short Bowel Syndrome market drivers and Short Bowel Syndrome market barriers
Request for Sample PDF Report for Short Bowel Syndrome Pipeline Assessment and clinical trials
Table of Contents
1. Short Bowel Syndrome Report Introduction
2. Short Bowel Syndrome Executive Summary
3. Short Bowel Syndrome Overview
4. Short Bowel Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Short Bowel Syndrome Pipeline Therapeutics
6. Short Bowel Syndrome Late Stage Products (Phase II/III)
7. Short Bowel Syndrome Mid Stage Products (Phase II)
8. Short Bowel Syndrome Early Stage Products (Phase I)
9. Short Bowel Syndrome Preclinical Stage Products
10. Short Bowel Syndrome Therapeutics Assessment
11. Short Bowel Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Short Bowel Syndrome Key Companies
14. Short Bowel Syndrome Key Products
15. Short Bowel Syndrome Unmet Needs
16 . Short Bowel Syndrome Market Drivers and Barriers
17. Short Bowel Syndrome Future Perspectives and Conclusion
18. Short Bowel Syndrome Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
